Evidence map›Paper›PMID 41430335›Full record

ArticleActa neuropathologica communications2025

YAP1::MAML2 fusion, a newly identified genetic anomaly in a posterior fossa infant tumor, associated with the methylation class "embryonal tumor with multilayered rosettes, non-C19MC-altered" in the Heidelberg central nervous system tumor classifier and "embryonal tumor with multilayered rosettes-DICER" in the NIH classifier.

Catherine Godfraind, Nabil Djebbour, Romain Appay, Anne Pagnier, Raia Doumit, Julien Masliah-Planchon, Fabien Forest, Fanny Burel-Vandenbos, Jean Boutonnat, Berengere Dadone-Montaudié

Abstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Catherine GodfraindNeuropathology Unit, University Hospital of Clermont-Ferrand, France, and UMR1071, Clermont Auvergne University, Clermont-Ferrand, France. cgodfraind@chu-clermontferrand.fr.
Nabil DjebbourLaboratory of Pathology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
Romain AppayNeuro-Pathology Department, AP-HM, University Hospital La Timone, Marseille, France.
Anne PagnierPediatric Oncology Department, University Hospital Center of Grenoble, Grenoble, France.
Raia DoumitPediatric Radiology Department, University Hospital Center of Grenoble, Grenoble, France.
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, Paris, France.
Fabien ForestDepartments of Pathology and Molecular Biology of Tumors, University Hospital of Saint Etienne, Saint Etienne, France.
Fanny Burel-VandenbosDepartment of Pathology, Nice University Hospital, Nice, France.
Jean BoutonnatPathology Department, University Hospital of Grenoble Alpes, Grenoble, France.
Berengere Dadone-MontaudiéInstitute for Research On Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, University of Cote d'Azur (UCA), Nice University Hospital, Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Embryonal tumors with multilayered rosettes (ETMR) are rare embryonal tumors that usually affect children under two years old. They are characterized histologically by the presence of multilayered rosettes and by the immunohistochemical expression of LIN28A. Their genetic hallmarks include C19MC amplification, which is most common, followed by DICER1 mutation. Each of these alterations correlates with a specific methylation class in the Heidelberg central nervous system tumor classifier and the National Institutes of Health brain tumor classifier. Meanwhile, 2.5 percent of LIN28A-positive embryonal tumors lack the previously mentioned genetic alterations associated with ETMR. Here, we present and discuss a case of this type. A posterior fossa tumor was found in a five-month-old infant. Histologically, the lesion appeared as an embryonal tumor, lacking multilayered rosettes but showing focal positivity for LIN28A. It did not show C19MC amplification or DICER1 mutation, yet it clustered within the ETMR non-C19MC-altered methylation class of the Heidelberg classifier (V12.5) and the ETMR-DICER class of the NIH classifier. Additionally, a YAP1::MAML2 fusion was identified, a finding not yet associated with these methylation classes.

Indexed as

Adaptor Proteins, Signal TransducingDNA-Binding ProteinsInfratentorial NeoplasmsNeoplasms, Germ Cell and EmbryonalNuclear ProteinsPhosphoproteinsTrans-ActivatorsDEAD-box RNA HelicasesDNA MethylationHumansInfantRibonuclease IIITranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingDEAD-box RNA HelicasesDICER1 protein, humanDNA-Binding ProteinsMAML2 protein, humanNuclear ProteinsPhosphoproteinsRibonuclease IIITrans-ActivatorsTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsDICER1 mutationETMRETMR DICER1-alteredETMR non-C19MC methylation classYAP1::MALM2 fusion

Identifiers

PMID41430335
PMCPMC12723895

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.